CorMedix
Biopharmaceutical company focused on developing, obtaining regulatory approvals for, and commercializing therapeutic products and antimicrobial medical devices to prevent and treat life‑threatening infections and related conditions. Core activities include clinical development (including pediatric programs), regulatory submissions and inspections, manufacturing oversight with contract manufacturers, and commercialization in institutional care settings.
Industries
Nr. of Employees
medium (51-250)
CorMedix
Patents
Antimicrobial compositions, including antimicrobial hydrogels, effective against mature biofilms
US-12302902-B2
View DetailsTaurultam, taurinamide and methylene glycol treatment for MYC—expressing tumors in mammalian bodies
US-12053478-B2
View DetailsMethods and pharmaceutical compositions for treating candida auris in blood
US-12016865-B2
View DetailsAntimicrobial wound closure materials, including antimicrobial sutures, and method for closing a wound using the same
US-10517984-B2
View Details
Antimicrobial compositions, including antimicrobial hydrogels, effective against mature biofilms
US-12302902-B2
View DetailsTaurultam, taurinamide and methylene glycol treatment for MYC—expressing tumors in mammalian bodies
US-12053478-B2
View DetailsMethods and pharmaceutical compositions for treating candida auris in blood
US-12016865-B2
View DetailsAntimicrobial wound closure materials, including antimicrobial sutures, and method for closing a wound using the same
US-10517984-B2
View DetailsProducts
DefenCath (taurolidine and heparin)
Catheter lock solution composed of an antimicrobial agent and heparin formulated to reduce catheter-related bloodstream infections in patients with central venous catheters undergoing hemodialysis.
Rezafungin (REZZAYO) — antifungal injection (licensed US rights)
IV antifungal agent approved for treatment of candidemia and invasive candidiasis in adults; being evaluated for prophylaxis of invasive fungal disease in allogeneic blood and marrow transplant patients.
Acquired anti-infective product portfolio (e.g., intravenous minocycline, meropenem-vaborbactam, oritavancin, delafloxacin)
Portfolio of injectable anti‑infective agents acquired and commercialized for hospital and acute care settings, including reformulated intravenous antibiotics and other agents used for serious and drug-resistant infections.
DefenCath (taurolidine and heparin)
Catheter lock solution composed of an antimicrobial agent and heparin formulated to reduce catheter-related bloodstream infections in patients with central venous catheters undergoing hemodialysis.
Rezafungin (REZZAYO) — antifungal injection (licensed US rights)
IV antifungal agent approved for treatment of candidemia and invasive candidiasis in adults; being evaluated for prophylaxis of invasive fungal disease in allogeneic blood and marrow transplant patients.
Acquired anti-infective product portfolio (e.g., intravenous minocycline, meropenem-vaborbactam, oritavancin, delafloxacin)
Portfolio of injectable anti‑infective agents acquired and commercialized for hospital and acute care settings, including reformulated intravenous antibiotics and other agents used for serious and drug-resistant infections.
Services
Sponsor-led clinical trials across adult and pediatric populations, including Phase 3 registration studies and post‑marketing surveillance.
Preparation of NDA and supplemental NDA submissions and coordination with regulatory authorities during review and inspections.
Negotiation and execution of multi‑year supply contracts and management of commercial distribution to large institutional providers.
Sponsor-led clinical trials across adult and pediatric populations, including Phase 3 registration studies and post‑marketing surveillance.
Preparation of NDA and supplemental NDA submissions and coordination with regulatory authorities during review and inspections.
Negotiation and execution of multi‑year supply contracts and management of commercial distribution to large institutional providers.
Expertise Areas
- Clinical trial management (Phase 1–4, pediatric studies)
- Catheter lock therapy development and evaluation
- Infectious disease therapeutics and anti‑infective product development
- Antimicrobial medical device and biomaterials development
Key Technologies
- Taurolidine-based antimicrobial formulations
- Catheter lock solution technology
- Sterile intravenous injectable formulation development
- Long-acting echinocandin antifungal agents (rezafungin)
News & Updates
Senior management participated in a fireside chat and investor meetings at the Needham Virtual Healthcare Conference.
Regular investor conference calls and webcasts to report quarterly financial results and corporate updates.
Industry coverage citing taurolidine-based approaches as an emerging option for treatment or prevention of catheter-related bloodstream infections.
U.S. FDA accepted for filing the resubmission of the New Drug Application for the catheter lock product as a complete Class 2 response (six-month review cycle).
Reported positive topline results from a Phase III trial assessing an antifungal agent for prophylaxis of invasive fungal disease in allogeneic hematopoietic stem cell transplant patients.
U.S. Court of Appeals affirmed judgment upholding patents covering a reformulated intravenous antibiotic and affirmed a permanent injunction against a proposed generic.
Senior management participated in a fireside chat and investor meetings at the Needham Virtual Healthcare Conference.
Regular investor conference calls and webcasts to report quarterly financial results and corporate updates.
Industry coverage citing taurolidine-based approaches as an emerging option for treatment or prevention of catheter-related bloodstream infections.
U.S. FDA accepted for filing the resubmission of the New Drug Application for the catheter lock product as a complete Class 2 response (six-month review cycle).
Reported positive topline results from a Phase III trial assessing an antifungal agent for prophylaxis of invasive fungal disease in allogeneic hematopoietic stem cell transplant patients.
U.S. Court of Appeals affirmed judgment upholding patents covering a reformulated intravenous antibiotic and affirmed a permanent injunction against a proposed generic.